Department of Pediatrics, Division of Rheumatology at Rady Children's Hospital, 3020 Childrens Way, San Diego, Ca, 92123, USA.
Department of Pediatrics, Division of Neurology at Children's Hospital at Montefiore, 3415 Bainbridge Ave, Bronx, NY, 10467, USA.
Pediatr Rheumatol Online J. 2020 Feb 11;18(1):15. doi: 10.1186/s12969-020-0412-8.
Neurological involvement has been reported in up to 80% of adults with Primary Sjogren's syndrome (pSS) with psychiatric abnormalities including anxiety, depression, and cognitive dysfunction being common. Psychosis due to pSS has been reported in adult patients but has never been previously reported in the adolescent/pediatric literature. Here we describe for the first time four cases of adolescent Sjogren's syndrome that presented with psychotic symptoms. Rituximab treatment was followed by improvement of psychiatric symptoms in all patients.
1: 16 year old female without significant past medical history presented to the emergency department with 4 days of abnormal behavior, tremors, insomnia, polyphagia, polyuria, and suicidal ideation. 2: 16 year old female with a 4 year history of severe anxiety, OCD, and tic disorder treated with fluoxetine with partial benefit presented with an abrupt and severe worsening of anxiety, OCD and new auditory hallucinations. 3: 19 year old female without significant past medical history presented with a 3 day history of progressively altered behavior, incoherent speech, insomnia, headache, and tangential thoughts. 4: 17 year old female without significant past medical history presented with new onset suicidal ideation, paranoia, confusion, and emotional lability.
Psychosis is more common in autoimmune disease than previously known. To our knowledge, the four teenage women described above are the first reported patients with adolescent pSS manifesting as psychosis. pSS should be considered in the differential diagnosis of young patients with new psychiatric disorders, even in the absence of sicca symptoms. Psychiatric symptoms improved with rituximab infusions in all 4 of our patients, which suggests rituximab may be an effective treatment option that should be considered early after the diagnosis of pSS-associated psychiatric disturbance.
原发性干燥综合征(pSS)患者中高达 80%存在神经系统受累,其中焦虑、抑郁和认知功能障碍等精神异常较为常见。pSS 导致的精神病在成年患者中已有报道,但在青少年/儿科文献中从未报道过。在此,我们首次描述了 4 例以精神病症状为表现的青少年干燥综合征患者。所有患者在接受利妥昔单抗治疗后精神症状均有所改善。
1:一名无明显既往病史的 16 岁女性因 4 天的异常行为、震颤、失眠、多食、多尿和自杀意念就诊于急诊。2:一名 16 岁女性,4 年前因严重焦虑、强迫症和抽动障碍接受氟西汀治疗,部分获益,现因焦虑、强迫症急剧恶化,且出现新的听觉幻觉而就诊。3:一名无明显既往病史的 19 岁女性因 3 天的行为逐渐改变、言语不连贯、失眠、头痛和离题思维就诊。4:一名无明显既往病史的 17 岁女性因新发自杀意念、偏执、意识模糊和情绪不稳就诊。
精神病在自身免疫性疾病中比以前所知更为常见。据我们所知,上述 4 名十几岁的女性是首例报道的表现为精神病的青少年 pSS 患者。对于出现新发精神障碍的年轻患者,即使无干燥症状,也应考虑 pSS。在我们的 4 例患者中,所有患者的精神病症状均在利妥昔单抗输注后改善,这表明利妥昔单抗可能是一种有效的治疗选择,应在诊断为 pSS 相关精神障碍后早期考虑。